Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest update is out from Alligator Bioscience AB ( (SE:ATORX) ).
Alligator Bioscience announced that it will present new data from its ongoing study of the CD40 agonist mitazalimab in combination with mFOLFIRINOX for metastatic pancreatic cancer at the ESMO Gastrointestinal Cancers Congress 2025. The study’s 24-month results indicate that patients receiving 900 μg/kg mitazalimab experienced significantly improved median overall survival and progression-free survival rates compared to chemotherapy alone, supporting the selection of this dose for Phase 3 trials, a decision recently endorsed by the FDA.
More about Alligator Bioscience AB
Alligator Bioscience is a biotechnology company specializing in the development of clinical-stage tumor-directed antibody drugs, focusing on the CD40 receptor. This approach aims to enhance T cell priming and counteract the tumor-specific immunosuppressive environment, offering potential benefits for cancer patients across various cancer types. The company’s lead drug candidate, mitazalimab, is advancing towards Phase 3 development and has shown promising survival data in metastatic pancreatic cancer patients.
Average Trading Volume: 370,600
Current Market Cap: SEK223M
Learn more about ATORX stock on TipRanks’ Stock Analysis page.